Stockscreener 앱 받기
20.24
2.07%
0.41
전일 마감가:
$19.83
열려 있는:
$20.04
하루 거래량:
1.78M
Relative Volume:
0.84
시가총액:
$1.96B
수익:
$352.57M
순이익/손실:
$-143.01M
주가수익비율:
-11.18
EPS:
-1.81
순현금흐름:
$-153.40M
1주 성능:
+3.69%
1개월 성능:
+9.52%
6개월 성능:
-11.73%
1년 성능:
-10.92%
1일 변동 폭
$19.94
$20.90
1주일 범위
$18.91
$20.90
52주 변동 폭
$13.53
$35.25
빔 테라퓨틱스 Stock (BEAM) Company Profile
명칭
Beam Therapeutics Inc
전화
857-327-8775
주소
26 LANDSDOWNE STREET, CAMBRIDGE, MA
BEAM을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BEAM
Beam Therapeutics Inc
|
20.24 | 1.96B | 352.57M | -143.01M | -153.40M | -1.81 |
|
VRTX
Vertex Pharmaceuticals Inc
|
501.15 | 126.96B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
605.61 | 65.06B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
649.67 | 37.54B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
259.39 | 32.56B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
255.77 | 26.40B | 3.81B | -644.79M | -669.77M | -6.24 |
빔 테라퓨틱스 Stock (BEAM) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-03-28 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2025-03-10 | 업그레이드 | Scotiabank | Sector Perform → Sector Outperform |
| 2025-01-29 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2024-11-06 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2024-10-16 | 개시 | Scotiabank | Sector Outperform |
| 2024-07-23 | 개시 | H.C. Wainwright | Buy |
| 2024-01-29 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2023-12-15 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2023-12-08 | 다운그레이드 | Jefferies | Buy → Hold |
| 2023-10-20 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2023-10-20 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2023-03-21 | 개시 | Bernstein | Mkt Perform |
| 2023-02-01 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-12-20 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2022-12-13 | 개시 | Citigroup | Buy |
| 2022-06-17 | 개시 | BMO Capital Markets | Market Perform |
| 2022-04-28 | 개시 | Credit Suisse | Neutral |
| 2022-01-05 | 개시 | Guggenheim | Buy |
| 2021-10-19 | 개시 | SVB Leerink | Outperform |
| 2021-09-24 | 재개 | Stifel | Buy |
| 2021-09-10 | 개시 | BofA Securities | Buy |
| 2021-05-11 | 개시 | Redburn | Buy |
| 2021-05-04 | 개시 | RBC Capital Mkts | Sector Perform |
| 2021-03-01 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2021-02-16 | 개시 | Wells Fargo | Overweight |
| 2021-01-29 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2021-01-06 | 개시 | Stifel | Hold |
| 2020-08-05 | 개시 | William Blair | Outperform |
| 2020-03-02 | 개시 | Barclays | Overweight |
| 2020-03-02 | 개시 | JP Morgan | Overweight |
| 2020-03-02 | 개시 | Jefferies | Buy |
| 2020-03-02 | 개시 | Wedbush | Outperform |
모두보기
빔 테라퓨틱스 주식(BEAM)의 최신 뉴스
Sage Therapeutics' Q1 Earnings Miss Mark, Revenue Rise Y/Y - TradingView
Next Generation Genome Editing Market Future Business - openPR.com
(BEAM) Investment Analysis and Advice - news.stocktradersdaily.com
BEAM to Discuss Advances in AATD Therapy at Upcoming Conference Call | BEAM Stock News - GuruFocus
Beam Therapeutics to Report Q1 Earnings: What's in the Cards? - MSN
Cathie Wood’s ARK Sells Adaptive Biotech, Buys Beam Therapeutics Stock By Investing.com - Investing.com Nigeria
Cathie Wood’s ARK Sells Adaptive Biotech, Buys Beam Therapeutics Stock - Investing.com
Sickle Cell Disease Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies - The Globe and Mail
Prime Editing and CRISPR Market is Expected to Reach $23.49 - openPR.com
Wolverine World Wide, Pacira BioSciences And Other Big Stocks Moving Higher On Monday - Benzinga
Recent uptick might appease Beam Therapeutics Inc. (NASDAQ:BEAM) institutional owners after losing 29% over the past year - simplywall.st
How To Trade (BEAM) - news.stocktradersdaily.com
Beam Therapeutics (BEAM) Moves 12.6% Higher: Will This Strength Last? - MSN
Beam Therapeutics Inc.'s (NASDAQ:BEAM) recent 11% pullback adds to one-year year losses, institutional owners may take drastic measures - Yahoo Finance
Cathie Wood's ARK ETF focuses on Beam Therapeutics, Coinbase stock - Investing.com
Biotech Firm Uncovers Gene Therapy Breakthrough in Portugal - streetwisereports.com
Share Price Appreciation of Biotech Due Over Next Six Months - streetwisereports.com
H.C. Wainwright maintains $80 target on Beam Therapeutics stock By Investing.com - Investing.com India
Beam Therapeutics Presents Biomarker Data For BEAM-302 Gene Therapy For Inherited Disease - AOL.com
H.C. Wainwright maintains $80 target on Beam Therapeutics stock - Investing.com
Beam Therapeutics Presents Additional Data for BEAM-302 in - GlobeNewswire
Beam Presents Addl. Data From Phase 1/2 Trial Of BEAM-302 In Alpha-1 Antitrypsin Deficiency - Nasdaq
Breakthrough: New BEAM-302 Data Shows 91% Success Rate in Rare Liver Disease Treatment - Stock Titan
Cathie Wood Just Made A Bold Move—Why She Spent Over $65M On Tesla, Robinhood, And Coinbase 'As The Market Crashed' - Benzinga
Beam Therapeutics executive sells $55,330 in stock By Investing.com - Investing.com South Africa
Beam Therapeutics executive sells $55,330 in stock - Investing.com Australia
Beam Therapeutics’ chief legal officer sells $104,121 in stock By Investing.com - Investing.com Canada
Beam Therapeutics’ chief legal officer sells $104,121 in stock - Investing.com India
Beam Therapeutics CEO John Evans sells $562,684 in stock By Investing.com - Investing.com India
Beam Therapeutics CEO John Evans sells $562,684 in stock - Investing.com
Beam Therapeutics president sells $136,418 in stock - Investing.com
Beam Therapeutics Executives Sell Shares for Tax Obligations and Personal Sales - TradingView
7 Top Gene-Editing Stocks to Buy | Investing | U.S. News - Money/ US News
Gene Editing: CRISPR Therapeutics vs. Beam Therapeutics - Securities.io
Beam Therapeutics Becomes Oversold - Nasdaq
Is Beam Therapeutics Inc. (BEAM) the Best Gene-Editing Stock to Buy? - Yahoo Finance
8 Best Gene-Editing Stocks to Buy - Insider Monkey
Biotech stocks plunge as FDA’s Peter Marks resigns over RFK Jr. dispute, Moderna and Beam Therapeutics hit hard - TradingView
Beam Therapeutics’ SWOT analysis: base editing pioneer faces gene therapy hurdles - Investing.com Canada
Beam Therapeutics’ SWOT analysis: base editing pioneer faces gene therapy hurdles By Investing.com - Investing.com South Africa
The Zacks Analyst Blog Highlights Illumina, BEAM, Twist Bioscience, Wave Life Sciences and CRISPR Therapeutics - Yahoo Finance
BEAM's IND for BEAM-302 in Genetic Disorder Study Gets FDA Clearance - MSN
Beam Therapeutics (BEAM) Upgraded to Buy by Bank of America on P - GuruFocus
Beam Therapeutics (BEAM) Upgraded by BofA on Promising Genetic T - GuruFocus
B of A Securities Upgrades Beam Therapeutics (BEAM) - MSN
Beam upgraded to Buy at BofA Securities on recent genetic condition treatment - Seeking Alpha
Beam Therapeutics stock rises after FDA clearance for BEAM-302 IND By Investing.com - Investing.com South Africa
Beam Therapeutics stock rises after FDA clearance for BEAM-302 IND - Investing.com
빔 테라퓨틱스 (BEAM) 재무 분석
매출
순이익
현금흐름
주당 순 이익
빔 테라퓨틱스 주식 (BEAM) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Evans John M. | CEO |
Apr 01 '25 |
Sale |
18.35 |
30,663 |
562,684 |
986,249 |
| Ciaramella Giuseppe | President |
Apr 01 '25 |
Sale |
18.35 |
7,434 |
136,418 |
190,216 |
| Cavanagh Bethany J | SVP, Finance and Treasurer |
Apr 01 '25 |
Sale |
18.35 |
3,015 |
55,330 |
44,512 |
| Simon Amy | Chief Medical Officer |
Apr 02 '25 |
Sale |
17.73 |
20,997 |
372,294 |
65,742 |
| Simon Amy | Chief Medical Officer |
Apr 01 '25 |
Sale |
18.35 |
9,566 |
175,542 |
86,739 |
0.47%
2.63%
자본화:
|
볼륨(24시간):